Richard A. Miller M.D.
Net Worth

Last updated:

What is Richard A. Miller M.D. net worth?

The estimated net worth of Dr. Richard A. Miller M.D. is at least $5,600,635 as of 6 May 2024. He owns shares worth $2,873,635 as insider and has received compensation worth at least $2,727,000 in Corvus Pharmaceuticals, Inc..

What is the salary of Richard A. Miller M.D.?

Dr. Richard A. Miller M.D. salary is $303,000 per year as Co-Founder, Pres, Chief Executive Officer & Chairman in Corvus Pharmaceuticals, Inc..

How old is Richard A. Miller M.D.?

Dr. Richard A. Miller M.D. is 74 years old, born in 1951.

What stocks does Richard A. Miller M.D. currently own?

As insider, Dr. Richard A. Miller M.D. owns shares in one company:

Company Title Shares Price per share Total value
Corvus Pharmaceuticals, Inc. (CRVS) Co-Founder, Pres, Chief Executive Officer & Chairman 559,073 $5.14 $2,873,635

What does Corvus Pharmaceuticals, Inc. do?

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The company also develops CPI-818, a covalent inhibitor of ITK, which is in Phase I/Ib clinical trial to treat patients with various malignant T-cell lymphomas, as well as designed to inhibit the proliferation of certain malignant T-cells; and Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor that is in Phase II clinical trial for patients with either advanced or refractory renal cell cancer. Its preclinical stage products include CPI-182, an antibody designed to block inflammation and myeloid suppression; and CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a strategic collaboration with Angel Pharmaceuticals for the development its pipeline of targeted investigational medicines. The company was incorporated in 2014 and is based in Burlingame, California.

CRVS logo
CRVS
Corvus Pharmaceuticals, Inc.
$5.14

Richard A. Miller M.D. insider trading

Corvus Pharmaceuticals, Inc.

Transaction Date Security Shares Price per share Total value Source
Purchase
Warrant (Right to Buy) 559,073 $3.5 $1,956,756
Purchase
Common Stock 577,634 $1.73 $999,884
Purchase
Common Stock 10,000 $0.78 $7,810
Purchase
Common Stock 50,000 $0.74 $37,000
Purchase
Common Stock 25,000 $0.76 $19,075
Purchase
Common Stock 12,300 $0.81 $9,963
Purchase
Common Stock 5,000 $0.82 $4,075
Purchase
Common Stock 2,700 $0.82 $2,214
Purchase
Common Stock 5,000 $1 $4,985
Purchase
Common Stock 5,000 $1.03 $5,150
Purchase
Common Stock 890 $1.01 $899
Purchase
Common Stock 170 $0.97 $165
Purchase
Common Stock 4,830 $0.98 $4,733
Purchase
Common Stock 15,000 $1.64 $24,540
Purchase
Common Stock 5,000 $1.59 $7,950
Purchase
Common Stock 25,000 $1.47 $36,650
Purchase
Common Stock 10,000 $1.93 $19,250
Purchase
Common Stock 35,714 $2.8 $99,999
Purchase
Common Stock 100,000 $3.5 $350,000
Purchase
Common Stock 14,736 $3 $44,237
Purchase
Common Stock 272 $2.9 $789
Purchase
Common Stock, $0.0001 par value 2,500 $3.54 $8,850
Purchase
Common Stock, $0.0001 par value 5,000 $3.58 $17,875
Purchase
Common Stock, $0.0001 par value 11,657 $3.4 $39,669
Purchase
Common Stock, $0.0001 par value 343 $3.52 $1,207
Purchase
Common Stock, $0.0001 par value 6,000 $3.67 $22,020
Purchase
Common Stock, $0.0001 par value 9,212 $3.37 $31,017
Purchase
Common Stock, $0.0001 par value 20,000 $3.29 $65,880
Purchase
Common Stock, $0.0001 par value 10,000 $4.39 $43,900
Purchase
Common Stock, $0.0001 par value 5,000 $5.99 $29,935
Purchase
Common Stock, $0.0001 par value 1,502 $5.95 $8,937
Purchase
Common Stock, $0.0001 par value 100,000 $8.5 $850,000
Purchase
Common Stock, $0.0001 par value 10,000 $10.79 $107,850
Purchase
Common Stock, $0.0001 par value 5,000 $10.14 $50,700
Purchase
Common Stock, $0.0001 par value 11,216 $9.82 $110,186
Purchase
Common Stock, $0.0001 par value 8,784 $9.92 $87,137
Purchase
Common Stock, $0.0001 par value 300 $9.94 $2,981
Purchase
Common Stock, $0.0001 par value 30,000 $10 $300,000

Corvus Pharmaceuticals key executives

Corvus Pharmaceuticals, Inc. executives and other stock owners filed with the SEC: